×

[Review] Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition

Cardiovascular, respiratory, and related disorders (CVRDs) are the leading causes of adult death worldwide, and substantial inequalities in care of patients with CVRDs exist between countries of high income and countries of low and middle income. Based on current trends, the UN Sustainable Development Goal to reduce premature mortality due to CVRDs by a third by 2030 will be challenging for many countries of low and middle income. We did systematic literature reviews of effectiveness and cost-effectiveness to identify priority interventions.

[Comment] Challenges in reducing influenza-associated mortality

In The Lancet, Danielle Iuliano and colleagues1 have attempted to estimate the global mortality burden of seasonal influenza. This study provides a much needed update to the often cited but unsubstantiated WHO-attributed estimate of 250 000–500 000 annual influenza deaths. The authors used country-specific, influenza-associated excess respiratory mortality estimates from 1999 to 2015, to calculate a new estimate of 291 243–645 832 seasonal influenza-associated respiratory deaths per year (4·0–8·8 per 100 000 individuals).

[Department of Error] Department of Error

Sinharay R, Gong J, Barratt B, et al. Respiratory and cardiovascular responses to walking down a traffic-polluted road compared with walking in a traffic-free area in participants older than 60 years with chronic lung or heart disease and age-matched healthy controls: a randomised, crossover study. Lancet 2017; 391: 339–49—In this Article (published online first on Dec 5, 2017), the corresponding author has been corrected, the middle initial for Frank Kelly has been added, the role of the funding source has been updated, and author initials have been updated throughout.

[Perspectives] Ian Pavord: engaging with the eosinophil

It says something for Ian Pavord’s modesty, self-confidence, or both that when talking of the insight with which he’s most closely associated, he cheerfully volunteers that it was a rediscovery of something first noted more than 50 years ago. In the 1990s, as a consultant respiratory physician and later an honorary professor at the UK’s University of Leicester, Pavord was studying eosinophils and inflammation. He’d acquired an interest in the topic during a fellowship at McMaster University in Hamilton, ON, Canada, where he worked for Freddy Hargreave, an inspirational English physician who, Pavord says, “probably trained more professors of respiratory medicine than anyone else in my era”.

[Seminar] Measles

Measles is a highly contagious disease that results from infection with measles virus and is still responsible for more than 100 000 deaths every year, down from more than 2 million deaths annually before the introduction and widespread use of measles vaccine. Measles virus is transmitted by the respiratory route and illness begins with fever, cough, coryza, and conjunctivitis followed by a characteristic rash. Complications of measles affect most organ systems, with pneumonia accounting for most measles-associated morbidity and mortality.

OPINION – Can safer surgery be legislated?

BY DR PETER SUBRAMANIAM

 In June, a Royal Australasian College of Surgeons Queensland Audit of Surgical Mortality report sparked Queensland government action that may trigger new federal and state laws for public reporting of patient safety data across public and private hospitals. By August, Queensland had released a discussion paper and its push for such standards nationally was supported by federal and state health ministers at COAG Health Council. The Council tasked the Australian Commission on Safety and Quality in Health Care to work with ‘interested jurisdictions’ on such standards and to incorporate the work into national performance and reporting frameworks.

Compliance with audits of surgical mortality like the Queensland report is a mandated professional practice requirement for all surgeons while all public hospitals and almost all private hospitals already participate in the audits. So, the question doesn’t appear to be hospitals’ compliance with public reporting of performance data on patients admitted to hospital under a surgeon. The relevant questions seem to be what constitutes metrics of patient safety-oriented surgical performance and whether legislation can protect patients’ safety.

What are the metrics of patient safety-oriented surgical performance?

Patients admitted under a surgeon in a hospital are treated by a surgical team regulated by the hospital’s organisational framework that is part of a public or private hospital network. So, correctly, the metrics of patient safety-oriented surgical performance are metrics of the effectiveness of both surgical team performance and organisational performance of the hospital and its parent organisation. Only if both sets of metrics are reported will the public be fully informed about whether the hospital, public or private, is effective at protecting their safety.

This concept of patient safety-oriented surgical performance is backed by evidence. Patient safety depends on effective surgical team communication and adverse events by individual surgical team members are typically rooted in faulty systems and inadequate organisational structures. This evidence is reflected in local experience of more than 33,000 cases over eight years reported in the Australian and New Zealand Audit of Surgical Mortality National Report 2016. Its key points include that surgical team communication is a key element of good patient care and delayed inter-hospital transfers of patients with limited reserves can significantly affect surgical outcomes.

So, metrics of patient safety-oriented surgical performance must show effective surgical team communication as being timely decisions and actions to prevent, diagnose and treat surgical complications and deteriorating patients e.g. prompt resuscitation and surgery for postoperative bleeding. Likewise, such metrics must also show effective hospital and parent organisational systems enabling surgical teams’ decisions in a way that protects patient safety e.g. prompt inter-hospital transfers, timely ICU bed and OR access, safe working hours and staff levels.

Can legislation protect surgical patient safety?

The results of the Australian and New Zealand Audit of Surgical Mortality suggest surgical patient mortality represents a segment of Australia’s aging population who are at the extreme of life with co-morbidities that are a stronger predictor of death than the type of surgery. When an acute surgical condition supervenes, they have a rapidly shrinking window of opportunity with almost a quarter being irretrievable. They are prone to surgical complications which often leads to cardiac or respiratory failure with rapid deterioration and death. Nonetheless, surgical mortality in Queensland and nationally has been improving over the last eight years so it is difficult to envisage how new legislation will add much to improving surgical patient safety.

Is legislation necessary?

In 2016, a number of NSW private hospitals did not participate in the audit of surgical mortality despite compliance by all public and private hospitals in all other jurisdictions through the system funded by all State and Territory Governments. If legislation is to bring private hospitals in line with this public reporting system, it should be directed specifically for this reason. If it is to improve surgical patient safety or to inform patient choice, it is not clear how it will improve on the current public reporting system supported by governments. If a national performance and reporting framework is being developed, it should be directed at metrics of surgical team and organisational performance.

It remains to be seen if Government will be surgical in its approach to patient safety.

___________________________________________________________________________

Dr Peter Subramaniam MBBS MSurgEd FRACS is a cardiothoracic surgeon in Canberra who is currently pursuing a Juris Doctor law degree at the Australian National University. He established the Australian and New Zealand Cardiac and Thoracic Surgeons national cardiac surgery database in the ACT as well as the multidisciplinary ACT Cardiac Surgery Planning Group. He also has extensive experience in undergraduate and postgraduate surgical education.

Views expressed in the opinion article reflect those of the author and do not represent official policy of the AMA.

 

Nine steps to managing insomnia in primary care

 

It’s one of the most common reasons people visit their GPs, and the drugs used to treat it can be highly addictive. Insomnia can have nebulous causes and varying symptoms, which often make it difficult to manage.

A new Viewpoint published this month in JAMA brings together the latest evidence and recommendations for managing insomnia. The authors say insomnia disorder can be diagnosed if sleep difficulties occur at least three nights a week for at least three months, as long as the patient has had adequate opportunity for sleep and the sleeplessness cannot be explained by medications, substance abuse or any other disorder.

Cognitive behavioural treatment (CBT) is the recommended initial treatment for chronic insomnia. Brief behavioral treatment for insomnia, an approach derived from CBT, can also be used, and involves four simple interventions to help increase “sleep drive”:

  • Reducing time in bed to match actual sleep duration;
  • Getting up at the same time each day, regardless of sleep duration;
  • Not going to bed unless sleepy;
  • Not staying in bed unless asleep.

Pharmacological treatment is best for patients with acute insomnia, in conjunction with CBT, although the evidence for drugs in managing insomnia disorder remains weak. If medication is prescribed, the approved drugs for insomnia are benzodiazepines and benzodiazepine receptor agonists, the melatonin receptor agonist ramelteon, the tricyclic doxepin and the orexin receptor antagonist suvorexant. But these medications should be used only on a short-term basis, and in shared decision-making with the patient.

Here are are nine key steps to managing insomnia:

  • Assess sleep and daytime symptoms and treat any comorbid conditions.
  • For acute insomnia, consider a short-acting hypnotic (eg, temazepam or zolpidem 3-4 nights weekly for 3-4 weeks), then taper and discontinue.
  • For chronic insomnia disorder, start the patient on an cognitive behavioral intervention.
  • Assess sleep and daytime symptom response to treatment.
  • If symptoms continue with CBT, consider combined treatment using a drug appropriate for sleep onset or sleep maintenance symptoms.
  • If symptoms continue with pharmacotherapy, consider switching class of hypnotic (eg, benzodiazepine or benzodiazepine receptor agonist to doxepin, ramelteon, or suvorexant).
  • If symptoms continue, evaluate other contributing factors (eg, life events, new medical or psychiatric disorder) and address with psychosocial, behavioral, or medical treatment.
  • If the insomnia disorder is completely treatment-resistant, refer to a sleep specialist for evaluation of other sleep-wake disorders, including sleep apnea.
  • Monitor for long-term treatment response and sequelae such as depressive or anxiety disorder, substance use disorder, or neurodegenerative disorder.

Source: JAMA

Vitamin D cuts asthma attack risk: study

 

 

Asthmatics who take vitamin D supplements could halve their chances of winding up in hospital being treated for a serious asthma attack.

British researchers reviewed data from 955 people, mainly adults with mild-to-moderate asthma, involved in seven trials that tested the use of oral vitamin D supplements.

Use of the supplements lead to a 50 per cent drop in the number of people being admitted to a hospital emergency department because of an asthma attack, the study published in The Lancet Respiratory Medicine journal on Thursday said.

There was also a 30 per cent slide in the number of asthmatics needing to be treated with steroids, the researchers from Queen Mary University of London found.

The supplements were found to be particularly beneficial for people who had low levels of vitamin D.

“These results add to the ever-growing body of evidence that vitamin D can support immune function as well as bone health,” lead researcher Professor Adrian Martineau said.

“Vitamin D is safe to take and relatively inexpensive so supplementation represents a potentially cost-effective strategy to reduce this problem.”

About one-in-nine Australians have asthma, a long-term lung condition that makes the airways in the lungs particularly sensitive and can cause breathlessness, coughing and wheezing.

Asthma Australia chief executive Michele Goldman says while the findings are encouraging as they suggest vitamin D could be another possible way of managing asthma but people should not ditch their preventer medication.

“This could be an effective way to manage asthma in addition to taking your regular preventer medication but it should in no means ….be taken in place of the preventer medication,” Mrs Goldman said.

“Preventer medication remains the best way to treat underlying inflammation in the airway.”

You can read the full study here, and a linked comment here.

The quick fix that dramatically cuts antibiotic use

 

Simply asking patients to wait a couple of days to see if their symptoms resolve before filling their script substantially cuts antibiotic use, an Australian meta-analysis has found.

The Cochrane review, led by the University of Queensland’s Primary Care Clinical Unit, looked at 11 studies involving 3,500 patients with suspected common respiratory tract infections. It essentially found no significant clinical difference in outcomes between patients randomised to immediate prescription of antibiotics, delayed prescription, or no prescription.

There were also very low rates of complications or missed treatment of serious complications in those randomised to the ‘wait-and-see’ prescriptions.

But delaying prescription led to a massive drop in antibiotic use. Over 90% of patients with an immediate prescription filled it, compared with around 30% of those with a delayed prescription.

Patients were more satisfied with being given a delayed prescription compared with being given no prescription at all – a significant finding since it’s well recognised that some of the pressure to prescribe antibiotics comes from the patients themselves.

The studies reviewed involved acute respiratory tract infections, including cough, sore throat, colds and otitis media.

Lead author Dr Geoffrey Spurling said the review showed delayed prescribing could be an acceptable compromise if a doctor didn’t believe antibiotics were needed at the time of the consult, but was uneasy about adopting a ‘no-antibiotics’ approach.

“The evidence indicates that delayed prescribing is an effective strategy for reducing antibiotic use and now we need to get this message out the medical community,” he said. “Individual GPs can feel confident implementing this strategy for reducing antibiotic use as a way of treating infections if they are uncomfortable with not prescribing antibiotics.”

As outlined in research recently published in the MJA, Australia has a very high rate of prescribing antibiotics for respiratory tract infections, with antibiotics prescribed at 4-9 times more often than is recommended by therapeutic guidelines.

Australia’s Chief Medical Officer recently sent written warnings to the top 30% of antibiotic prescribers, asking them to think about what they can do to reduce their prescribing.

You can access the Cochrane Review here.